臺灣博碩士論文加值系統

本論文的研究目的是為了分析卵巢亮細胞癌（Ovarian clear cell adenocarcinoma, OCCA）與卵巢類子宮內膜癌（Ovarian endometrioid adenocarcinoma, OEA）之間不同基因的甲基化情形，並進一步評估基因甲基化是否可以當作預測病人化療反應與預後的生物指標。透過甲基化特異聚合&;#37238;連鎖反應（Methylation-Specific Polymerase Chain Reaction, MS-PCR）及毛細電泳等方法，我們在66個OCCA與51個OEA病人中，分析8個候選基因（RASSF1A、E-cadherin、DLEC1、RUNX3、SFRP1、SFRP5、PAX與LMX1A）中的甲基化情形，並收集與分析這些病人的臨床病理參數和預後。研究結果顯示，在OCCA的病人中，包括RASSF1A、E-cadherin、DLEC1這三個基因的甲基化頻率皆高於OEA的病人；而對化療藥有抗藥性的組別中，E-cadherin基因的甲基化比例相對於對化療藥敏感的組別明顯高出許多；另外，我們針對這117位病患進行多變量分析，發現疾病處於晚期及SFRP5基因的甲基化是與致死相關的危險因子。再進一步的分析中顯示，包括E-cadherin、DLEC1與SFRP5這三個基因中如果有兩個以上發生基因甲基化的情形，比起只有一個或沒有甲基化的組別，有較短的無病存活期（disease-free survival, DFS）和整體存活期（overall survival, OS）；針對57個癌症處於晚期的婦女分析，使用紫杉醇（paclitaxel）進行化療之組別的整體存活期也比沒使用紫杉醇的患者來的長。綜合以上結果，我們認為OCCA與OEA的甲基化型態確實不同，而E-cadherin、DLEC1和SFRP5這三個基因甲基化的情形，未來或許有發展為卵巢癌OCCA及OEA病患之預後生物指標的潛力。

The purpose of the thesis was to investigate the methylation of various genes between patients with ovarian clear cell adenocarcinoma (OCCA) and ovarian endometrioid adenocarcinoma (OEA). In addition, we evaluated if methylation could be biomarkers in the chemo-response and outcome of the patients. The methylation statuses of eight candidate genes (RASSF1A, E-cadherin, DLEC1, RUNX3, SFRP1, SFRP5, PAX and LMX1A) were evaluated by methylation-specific polymerase chain reactions and capillary electrophoreses in 66 OCCA and 51 OEA patients. The clinico-pathologic parameters and outcomes of these patients were collected and analyzed. The frequencies of gene methylation in RASSF1A, E-cadherin, and DLEC1 were higher in the OCCA than in OEA. The chemo-resistant group had a significantly higher percentage of E-cadherin methylation than the chemo-sensitive group. Advanced stage and SFRP5 gene methylation were two death risk factors by multi-variate analyses in a total of 117 patients. In further analyses, gene methylation of E-cadherin, DLEC1, and SFRP5 were observed. Those with more than two out of the three gene methylations had shorter DFS and OS than those without any or with only one gene methylation. For 57 advance-staged women, paclitaxel chemotherapeutic group had longer OS than those without. As a result, we believe OCCA and OEA differed in gene methylation patterns. Methylation of E-cadherin, DLEC1, and SFRP5 genes appears to have the potential to become the specific biomarkers for OCCA and OEA patients.

目 錄
口試委員會審定書………………………………………… i
誌謝………………………………………………………… ii
中文摘要…………………………………………………… iii
英文摘要…………………………………………………… iv
前言………………………………………………………… 1
材料方法…………………………………………………… 3
結果………………………………………………………… 6
討論………………………………………………………… 11


參考文獻…………………………………………………… 15

1.Jemal, A., et al., Global cancer statistics. CA Cancer J Clin, 2011. 61(2): p. 69-90.
2.Siegel, R., et al., Cancer statistics, 2014. CA Cancer J Clin, 2014. 64(1): p. 9-29.
3.Cancer Registration System Annual Report, Cancer Registration System, Department of Health: Taipei T.
4.Stuart, G.C., First-line treatment regimens and the role of consolidation therapy in advanced ovarian cancer. Gynecol Oncol, 2003. 90(3 Pt 2): p. S8-15.
5.Agarwal, R. and S.B. Kaye, Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer, 2003. 3(7): p. 502-16.
6.Barnholtz-Sloan, J.S., et al., Ovarian cancer: changes in patterns at diagnosis and relative survival over the last three decades. Am J Obstet Gynecol, 2003. 189(4): p. 1120-7.
7.Chan, J.K., et al., Patterns and progress in ovarian cancer over 14 years. Obstet Gynecol, 2006. 108(3 Pt 1): p. 521-8.
8.Chiaffarino, F., et al., Risk factors for ovarian cancer histotypes. Eur J Cancer, 2007. 43(7): p. 1208-13.
9.Vlahos, N.F., T. Kalampokas, and S. Fotiou, Endometriosis and ovarian cancer: a review. Gynecol Endocrinol, 2010. 26(3): p. 213-9.
10.Jimbo, H., et al., Prevalence of ovarian endometriosis in epithelial ovarian cancer. Int J Gynaecol Obstet, 1997. 59(3): p. 245-50.
11.Pectasides, D., et al., Advanced stage clear-cell epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience. Gynecol Oncol, 2006. 102(2): p. 285-91.
12.Mackay, H.J., et al., Prognostic relevance of uncommon ovarian histology in women with stage III/IV epithelial ovarian cancer. Int J Gynecol Cancer, 2010. 20(6): p. 945-52.
13.White, H.E., V.J. Hall, and N.C. Cross, Methylation-sensitive high-resolution melting-curve analysis of the SNRPN gene as a diagnostic screen for Prader-Willi and Angelman syndromes. Clin Chem, 2007. 53(11): p. 1960-2.
14.Egger, G., et al., Epigenetics in human disease and prospects for epigenetic therapy. Nature, 2004. 429(6990): p. 457-63.
15.Herman, J.G. and S.B. Baylin, Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med, 2003. 349(21): p. 2042-54.
16.Huang, Y.W., et al., An overview of epigenetics and chemoprevention. FEBS Lett, 2011. 585(13): p. 2129-36.
17.Shih Ie, M., et al., Distinct DNA methylation profiles in ovarian serous neoplasms and their implications in ovarian carcinogenesis. Am J Obstet Gynecol, 2010. 203(6): p. 584 e1-22.
18.Olopade, O.I. and M. Wei, FANCF methylation contributes to chemoselectivity in ovarian cancer. Cancer Cell, 2003. 3(5): p. 417-20.
19.Wei, S.H., et al., Prognostic DNA methylation biomarkers in ovarian cancer. Clin Cancer Res, 2006. 12(9): p. 2788-94.
20.Barton, C.A., et al., Epigenetic markers of ovarian cancer. Adv Exp Med Biol, 2008. 622: p. 35-51.
21.Herman, J.G., et al., Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A, 1996. 93(18): p. 9821-6.
22.Kagan, J., et al., Towards Clinical Application of Methylated DNA Sequences as Cancer Biomarkers: A Joint NCI''s EDRN and NIST Workshop on Standards, Methods, Assays, Reagents and Tools. Cancer Res, 2007. 67(10): p. 4545-9.
23.Teodoridis, J.M., et al., CpG island methylation of DNA damage response genes in advanced ovarian cancer. Cancer Res, 2005. 65(19): p. 8961-7.
24.Makarla, P.B., et al., Promoter hypermethylation profile of ovarian epithelial neoplasms. Clin Cancer Res, 2005. 11(15): p. 5365-9.
25.Kwong, J., et al., Candidate tumor-suppressor gene DLEC1 is frequently downregulated by promoter hypermethylation and histone hypoacetylation in human epithelial ovarian cancer. Neoplasia, 2006. 8(4): p. 268-78.
26.Rosenblatt, K.A. and D.B. Thomas, Reduced risk of ovarian cancer in women with a tubal ligation or hysterectomy. The World Health Organization Collaborative Study of Neoplasia and Steroid Contraceptives. Cancer Epidemiol Biomarkers Prev, 1996. 5(11): p. 933-5.
27.Su, H.Y., et al., Epigenetic silencing of SFRP5 is related to malignant phenotype and chemoresistance of ovarian cancer through Wnt signaling pathway. Int J Cancer, 2010. 127(3): p. 555-67.
28.Su, H.Y., et al., An epigenetic marker panel for screening and prognostic prediction of ovarian cancer. Int J Cancer, 2009. 124(2): p. 387-93.
29.Kurman, R.J. and M. Shih Ie, The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol, 2010. 34(3): p. 433-43.
30.Yoo, C.B. and P.A. Jones, Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov, 2006. 5(1): p. 37-50.
31.Veras, E., et al., Cystic and adenofibromatous clear cell carcinomas of the ovary: distinctive tumors that differ in their pathogenesis and behavior: a clinicopathologic analysis of 122 cases. Am J Surg Pathol, 2009. 33(6): p. 844-53.
32.Wiegand, K.C., et al., ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med, 2010. 363(16): p. 1532-43.
33.Rahman, M., et al., Clinicopathologic and biological analysis of PIK3CA mutation in ovarian clear cell carcinoma. Hum Pathol, 2012. 43(12): p. 2197-206.
34.Wu, R., et al., Mouse model of human ovarian endometrioid adenocarcinoma based on somatic defects in the Wnt/beta-catenin and PI3K/Pten signaling pathways. Cancer Cell, 2007. 11(4): p. 321-33.
35.Allen, N.P., et al., RASSF6 is a novel member of the RASSF family of tumor suppressors. Oncogene, 2007. 26(42): p. 6203-11.
36.Hesson, L.B., W.N. Cooper, and F. Latif, The role of RASSF1A methylation in cancer. Dis Markers, 2007. 23(1-2): p. 73-87.
37.Burbee, D.G., et al., Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. J Natl Cancer Inst, 2001. 93(9): p. 691-9.
38.Agathanggelou, A., et al., Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast and ovarian tumours. Oncogene, 2001. 20(12): p. 1509-18.
39.Vos, M.D., et al., Ras uses the novel tumor suppressor RASSF1 as an effector to mediate apoptosis. J Biol Chem, 2000. 275(46): p. 35669-72.
40.Esteller, M., CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future. Oncogene, 2002. 21(35): p. 5427-40.
41.Chan, A.O., et al., Promoter methylation of E-cadherin gene in gastric mucosa associated with Helicobacter pylori infection and in gastric cancer. Gut, 2003. 52(4): p. 502-6.
42.Graff, J.R., et al., Distinct patterns of E-cadherin CpG island methylation in papillary, follicular, Hurthle''s cell, and poorly differentiated human thyroid carcinoma. Cancer Res, 1998. 58(10): p. 2063-6.
43.Bornman, D.M., et al., Methylation of the E-cadherin gene in bladder neoplasia and in normal urothelial epithelium from elderly individuals. Am J Pathol, 2001. 159(3): p. 831-5.
44.Ying, J., et al., DLEC1 is a functional 3p22.3 tumour suppressor silenced by promoter CpG methylation in colon and gastric cancers. Br J Cancer, 2009. 100(4): p. 663-9.
45.Rosty, C., et al., p16 Inactivation in pancreatic intraepithelial neoplasias (PanINs) arising in patients with chronic pancreatitis. Am J Surg Pathol, 2003. 27(12): p. 1495-501.
46.Sato, N., et al., CpG island methylation profile of pancreatic intraepithelial neoplasia. Mod Pathol, 2008. 21(3): p. 238-44.
47.Ho, C.M., et al., Prognostic and predictive values of E-cadherin for patients of ovarian clear cell adenocarcinoma. Int J Gynecol Cancer, 2010. 20(9): p. 1490-7.
48.Wang, T.H., H.S. Wang, and Y.K. Soong, Paclitaxel-induced cell death: where the cell cycle and apoptosis come together. Cancer, 2000. 88(11): p. 2619-28.
49.Matei, D.E. and K.P. Nephew, Epigenetic therapies for chemoresensitization of epithelial ovarian cancer. Gynecol Oncol, 2010. 116(2): p. 195-201.
50.Bu, X.M., et al., Hypermethylation and aberrant expression of secreted frizzled-related protein genes in pancreatic cancer. World J Gastroenterol, 2008. 14(21): p. 3421-4.
51.Veeck, J., et al., Epigenetic inactivation of the secreted frizzled-related protein-5 (SFRP5) gene in human breast cancer is associated with unfavorable prognosis. Carcinogenesis, 2008. 29(5): p. 991-8.